Key result
Combining saroglitazar and gemfibrozil shows a favorable safety profile for T2DM and diabetic dyslipidemia.
Why the study?
Diabetics have an increased propensity to develop dyslipidemia, which exacerbates their cardiovascular risk and requires effective therapeutic strategies.
Does combination therapy of saroglitazar and gemfibrozil improve lipid profiles and insulin levels in experimental rats compared to individual drugs?
Does combination therapy of saroglitazar and gemfibrozil improve lipid profiles and insulin levels in experimental rats compared to individual drugs?
The combination of saroglitazar and gemfibrozil improves lipid profiles and insulin levels more effectively than monotherapy in a rat model of diabetic dyslipidemia.
Answers are grounded in this paper and cite their sources.
Supports safe saroglitazar-gemfibrozil use in T2DM dyslipidemia; hypothesis-generating for novel therapy and warrants larger trials.
INTRODUCTION: Diabetics have an increased cardiovascular risk. This risk gets exaggerated by lipid abnormalities additionally. Diabetics have an increased propensity to develop dyslipidemia. Diabetic dyslipidemia is a cluster of lipoprotein abnormalities characterized by increased triglyceride and low-density lipoprotein levels, decreased high-density lipoprotein levels. MATERIALS AND METHODS: From the pilot study, a potent dose of saroglitazar and gemfibrozil was selected for this study. In this study, the experimental rats were divided into five groups of six animals in each group. RESULTS: Combination therapy shows a decrease in lipid profile, atherogenic index, histopathological studies of different organs, and insulin levels compared to individual drugs and shows better therapeutic efficacy. CONCLUSION: Hence, the combination of saroglitazar and gemfibrozil has shown a good safety profile and may represent a novel therapeutic agent that will fulfill the unmet needs in T2DM and diabetic dyslipidemia.
No takes yet. Share an insight, caveat, or question.
Uma Maheswari (2026) studied Diabetic dyslipidemia (n=30). Combination of saroglitazar and gemfibrozil vs. Individual drugs was evaluated on Lipid profile, atherogenic index, histopathological studies, and insulin levels. Combination therapy with saroglitazar and gemfibrozil improved lipid profile, atherogenic index, and insulin levels compared to individual drugs in experimental rats.
Synapse has enriched 10 related papers. Consider them for comparative context: